Locally Delivered 1% Metformin Gel in the Treatment of Intrabony Defects in Chronic Periodontitis

Inclusion Criteria: * Systemically healthy subjects * Sites with probing depth (PD) ≥5 mm * Clinical attachment level (CAL) ≥4 mm * Vertical bone loss ≥3 mm on intraoral periapical radiographs with no history of periodontal therapy or use of antibiotics in the preceding 6 months were included Exclusion Criteria: * Patients with known systemic disease * Known or suspected allergy to the MF/ biguanide group * Patients on systemic MF or other oral antidiabetic therapy * Patients with aggressive periodontitis * Patients with diabetes * Use of tobacco in any form * Alcoholism * Immunocompromised patients * Pregnant or lactating females